Lawsuits are being filed against Sanofi and Regeneron, the manufacturers of Dupixent (dupilumab), alleging that the drug causes or accelerates T-Cell Lymphoma, specifically Cutaneous T-Cell Lymphoma (CTCL). The first wrongful death lawsuit was filed in October 2025, involving a patient who died from T-cell lymphoma shortly after starting the treatment.
Plaintiffs claim that the manufacturers failed to warn doctors and patients about these risks despite growing evidence. Studies have shown a significant increase in lymphoma risk for Dupixent users, yet the drug's warning label does not currently include T-cell lymphoma as a potential side effect.
Dupixent (dupilumab) is an FDA-approved prescription biologic used to treat moderate-to-severe eczema (atopic dermatitis), asthma, and chronic rhinosinusitis with nasal polyps. It works by blocking IL-4 and IL-13 proteins to inflammation. However, by suppressing specific immune pathways, it may also suppress the body's natural defense against abnormal cell growth, potentially leading to cancer.
If you developed T-Cell Lymphoma after taking Dupixent, you may be entitled to compensation for medical bills, lost wages, and pain and suffering.
You typically qualify if you:
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.